Page last updated: 2024-08-21

thiazolidines and Granulocytic Leukemia, Chronic

thiazolidines has been researched along with Granulocytic Leukemia, Chronic in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Aoki, S; Endo, S; Furuichi, K; Hirao, T; Ito, K; Kikuya, M; Toyooka, N	1
Brehm, MA; Green, MR; Hutchinson, L; Li, S; Ma, L; Ou, J; Pak, ML; Shan, Y; St Louis, P; Yu, J; Zhu, LJ	1

Other Studies

2 other study(ies) available for thiazolidines and Granulocytic Leukemia, Chronic

Article	Year
Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia. Journal of pharmacological sciences, 2021, Volume: 147, Issue:1 Topics: Aldehyde Reductase; Aldo-Keto Reductases; Aniline Compounds; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Glucose; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinolines; Rhodanine; Thiazolidines	2021
Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 05-21, Volume: 116, Issue:21 Topics: Animals; bcl-Associated Death Protein; Biphenyl Compounds; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Targeted Therapy; Neoplastic Stem Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; STAT Transcription Factors; Thiazolidines	2019

Article

Year

Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia.

Journal of pharmacological sciences, 2021, Volume: 147, Issue:1

Topics: Aldehyde Reductase; Aldo-Keto Reductases; Aniline Compounds; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Glucose; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinolines; Rhodanine; Thiazolidines

2021

Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells.

Proceedings of the National Academy of Sciences of the United States of America, 2019, 05-21, Volume: 116, Issue:21

Topics: Animals; bcl-Associated Death Protein; Biphenyl Compounds; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Targeted Therapy; Neoplastic Stem Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; STAT Transcription Factors; Thiazolidines

2019